Claims that Bayer AG is moving away from women’s health are not correct, the German major has told Scrip, although the space will not be a priority for its early research efforts.
Women’s Health Still Key to Bayer Despite Early Research Shift
Exit Rumors Inaccurate
The German major has pinned its early-stage research colors to the masts of oncology, cardiovascular, neurology, rare diseases and immunology, representing a shift away from rather than an abandonment of women’s health.
More from Women's Health
• By
Deal Snapshot: Cosette will acquire struggling Mayne Pharma for about $430m, thereby augmenting its women’s health and dermatology portfolio and enhancing commercial capabilities.
• By
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
• By
Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.
• By
Interim results from an international Phase II study with its prolactin inhibiting antibody have boosted HopeMed’s confidence in its first-line potential in the chronic disorder, the Chinese venture's CEO tells Scrip.
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.